HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

AbstractPURPOSE:
Transforming growth factors (TGFs) have pleiotropic biological effects on tumor cells and their environment. In multiple myeloma (MM), we have reported that bone marrow stromal cells (BMSCs) from MM patients produce more TGF-beta1 than BMSCs from healthy donors, which in turn induces interleukin (IL)-6 secretion. We show here that the TGF-beta receptor I kinase inhibitor SD-208 significantly decreases secretion of both IL-6 and vascular endothelial growth factor (VEGF) from BMSCs, as well as tumor cell growth triggered by MM cell adhesion to BMSCs.
EXPERIMENTAL DESIGN:
Cytokine production and MM cell proliferation triggered by TGF-beta1 or adhesion to BMSCs were examined in the presence or absence of SD-208. Effects of SD-208 on TGF-beta1-induced signaling pathways triggering IL-6 and VEGF transcription in BMSCs were also delineated.
RESULTS:
SD-208 significantly inhibits not only transcription but also secretion of both IL-6 and VEGF from BMSCs triggered by either TGF-beta1 or adhesion of MM cells to BMSCs. Moreover, SD-208 decreased tumor cell growth triggered by MM cell adhesion to BMSCs. SD-208 works, at least in part, by blocking TGF-beta1-triggered nuclear accumulation of Smad2/3 and hypoxia-inducible factor 1alpha, as well as related production of IL-6 and VEGF, respectively.
CONCLUSIONS:
These studies indicate that SD-208 inhibits production of cytokines mediating MM cell growth, survival, drug resistance, and migration in the BM milieu, thereby providing the preclinical rationale for clinical evaluation of SD-208 to improve patient outcome in MM.
AuthorsToshiaki Hayashi, Teru Hideshima, Aaron N Nguyen, Olivier Munoz, Klaus Podar, Makoto Hamasaki, Kenji Ishitsuka, Hiroshi Yasui, Paul Richardson, Sarvajit Chakravarty, Alison Murphy, Dharminder Chauhan, Linda S Higgins, Kenneth C Anderson
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 10 Issue 22 Pg. 7540-6 (Nov 15 2004) ISSN: 1078-0432 [Print] United States
PMID15569984 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Cytokines
  • Enzyme Inhibitors
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Interleukin-6
  • Receptors, Transforming Growth Factor beta
  • Transcription Factors
Topics
  • Antineoplastic Agents (pharmacology)
  • Bone Marrow (metabolism)
  • Bone Marrow Cells (cytology, metabolism)
  • Cell Adhesion
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cytokines (biosynthesis, metabolism)
  • Down-Regulation
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Immunoblotting
  • Interleukin-6 (metabolism)
  • Lymphocytes (cytology)
  • Microscopy, Fluorescence
  • Multiple Myeloma (metabolism)
  • Receptors, Transforming Growth Factor beta (antagonists & inhibitors)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction
  • Transcription Factors (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: